Kazia advances paxalisib colorectal cancer program
- Kazia Therapeutics reported paxalisib reduced tumor burden by 52% in a colorectal cancer model.
- The company plans a five-arm Phase 2 trial in metastatic colorectal cancer starting in 2027.
- Paxalisib combinations with immunotherapy are being evaluated for potential treatment approaches.
Kazia Therapeutics (NASDAQ:KZIA) reported preclinical data showing its PI3K/mTOR inhibitor paxalisib reduced tumor burden by 52% in an MSS/pMMR colorectal cancer model.
The company said a separate study showed adding paxalisib to checkpoint inhibitor immunotherapy reduced tumor volume by an additional 50% compared with immunotherapy alone, with both studies reporting no treatment-related toxicity.
Kazia said it is developing a biomarker program to identify molecular, immune, and epigenetic signatures linked to paxalisib response and has filed a new patent related to colorectal cancer applications.
The company plans to begin enrollment in a five-arm Phase 2 trial in pre-treated MSS/pMMR metastatic colorectal cancer in the first quarter of 2027.
Kazia Therapeutics develops targeted cancer therapies focused on oncology indications, including treatments designed to affect tumor signaling pathways.
The planned Phase 2 study will evaluate paxalisib alone and in combination with pembrolizumab against standard-of-care treatments, with full enrollment across all five arms expected by the end of 2027.
